01—Abstract
Summary
Summary of the 8-K filed December 22, 2025. Cited figures are marked; the original filing is the authoritative source.
Royalty Pharma plc (RPRX) filed this Current Report on Form 8-K dated December 22, 2025 under Item 5.02, disclosing a leadership transition in its legal function.
George W. Lloyd, age 66, informed the company on December 20, 2025 of his decision to step down as Executive Vice President and Chief Legal Officer effective December 31, 2025. He will remain with the company as a senior advisor.
Arthur R. McGivern, age 50, Executive Vice President and General Counsel, will assume Mr. Lloyd's responsibilities effective January 1, 2026. Mr. McGivern joined the company in October 2022 and previously was a partner at Goodwin Procter LLP.
The filing also states that Mr. Lloyd and the company have agreed to terminate his Executive Offer Letter dated May 16, 2025, effective December 31, 2025, and that he will enter into the company's standard form employee offer letter effective January 1, 2026. The filing contains no financial results or compensation figures.
02—Key points
Key Highlights
- George W. Lloyd, Executive Vice President and Chief Legal Officer, is transitioning out of the role effective December 31, 2025, and will remain as a senior advisor.
- Arthur R. McGivern, Executive Vice President and General Counsel, will assume Mr. Lloyd's responsibilities effective January 1, 2026.
- Mr. McGivern joined Royalty Pharma in October 2022 and previously was a partner at Goodwin Procter LLP.
- Mr. Lloyd's Executive Offer Letter dated May 16, 2025 will be terminated effective December 31, 2025.
- Mr. Lloyd will enter the company's standard form employee offer letter effective January 1, 2026.
- Mr. Lloyd informed the company of his decision on December 20, 2025.
03—Questions
Frequently Asked Questions
Who is leaving the company's legal leadership role?
George W. Lloyd, age 66, is transitioning from his role as Executive Vice President and Chief Legal Officer effective December 31, 2025. He will remain employed by the company as a senior advisor.
Who is replacing Mr. Lloyd?
Arthur R. McGivern, age 50, Executive Vice President and General Counsel, will assume Mr. Lloyd's responsibilities effective January 1, 2026.
What is Mr. McGivern's background?
Mr. McGivern joined Royalty Pharma in October 2022. Before that, he was a partner at Goodwin Procter LLP.
How is Mr. Lloyd's employment arrangement changing?
The company and Mr. Lloyd have agreed to terminate his Executive Offer Letter dated May 16, 2025, effective December 31, 2025. He will enter into the company's standard form employee offer letter effective January 1, 2026.
04—Continue